NGM Biopharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€3.81M - Cost of goods sold
€2.81M - Gross profit
€1.00M - SG&A expenses
€32.66M - R&D expenses
€101.43M - EBITDA
-€129.33M - D&A
€1.92M - EBIT
-€130.72M - Interest expenses
€2.20M - EBT
-€122.87M - Tax expenses
-€2.20M - Net income
-€120.68M
Cash flow statement
- Net deferred tax
-€10.46M - Non-cash items
€8.40M - Changes in working capital
-€15.86M - Operating cash flow
-€114.10M - Capex
€1.08M - Other investing cash flow
-€0.00 - Net investing cash flow
€98.63M - Total cash dividends paid
€0.00 - Issuance of common stock
€1.53M - Debt repayment
€0.00 - Other financing cash flow
€1.53M - Net financing cash flow
€1.53M - Foreign exchange effects
€0.00 - Net change in cash
-€13.93M - Cash at end of period
€50.76M - Free cash flow
-€113.01M
Balance sheet
- Cash and cash equivalents
€50.76M - Cash and short-term investments
€127.03M - Total receivables
€50.06K - Inventory
€0.00 - Other current assets
€7.94M - Total current assets
€135.02M - Property, plant & equipment
€6.07M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€2.12M - Other non-current assets
€2.53M - Total non-current assets
€10.72M - Total assets
€145.74M - Accounts payable
€2.57M - Short-term debt
€0.00 - Other current liabilities
€14.76M - Total current liabilities
€17.33M - Long-term debt
€0.00 - Deferred tax liabilities
€0.00 - Other non-current liabilities
€128.59K - Total non-current liabilities
€128.59K - Total liabilities
€17.46M - Common stock
€71.63K - Retained earnings
-€624.85M - Other equity
€15.53K - Total equity
€128.28M - Total liabilities and shareholders' equity
€145.74M
Company information
- Market capitalization
€109.63M - Employees
138 - Enterprise Value
€69.72M
Company ratios
- Gross margin
-
26.3% Much better than peer group: -1,731,042,299,925.5% - EBITDA margin
-
-3,392.6% Much better than peer group: -4,094,781,511,773.7% - EBIT margin
-
-3,429.1% Much better than peer group: -4,330,061,447,924.2% - EBT margin
-
-3,223.3% Much better than peer group: -4,155,192,984,207.9% - Net margin
-
-3,165.7% Much better than peer group: -4,155,192,986,272.0% - ROE
-
-94.1% Much better than peer group: -402.8% - ROA
-
-82.8% Better than peer group: -100.8% - Asset turnover
-
2.6% Much better than peer group: -852.1% - FCF margin
-
-3,021.4% Much better than peer group: -3,461,705,221,583.0% - FCF yield
-105.1% - Efficiency ratio
3,492.6% - Net sales per employee
-
€27.62K - Net income per employee
-
-€874.47K